RESUMEN
One of the chief advantages of using highly standardised biological models including model organisms is that multiple variables can be precisely controlled so that the variable of interest is more easily studied. However, such an approach often obscures effects in sub-populations resulting from natural population heterogeneity. Efforts to expand our fundamental understanding of multiple sub-populations are in progress. However, such stratified or personalised approaches require fundamental modifications of our usual study designs that should be implemented in Brain, Behavior and Immunity (BBI) research going forward. Here we explore the statistical feasibility of asking multiple questions (including incorporating sex) within the same experimental cohort using statistical simulations of real data. We illustrate and discuss the large explosion in sample numbers necessary to detect effects with appropriate power for every additional question posed using the same data set. This exploration highlights the strong likelihood of type II errors (false negatives) for standard data and type I errors when dealing with complex genomic data, where studies are too under-powered to appropriately test these interactions. We show this power may differ for males and females in high throughput data sets such as RNA sequencing. We offer a rationale for the use of alternative experimental and statistical strategies based on interdisciplinary insights and discuss the real-world implications of increasing the complexities of our experimental designs, and the implications of not attempting to alter our experimental designs going forward.
Asunto(s)
Experimentación Animal , Proyectos de Investigación , Masculino , Animales , CausalidadRESUMEN
The balance of inflammation and immunosuppression driven by changed ratios in diverse myeloid and T cell subsets, as well as their state of activation and ability to migrate to lymphoid compartments or inflammatory sites, has emerged as a highly active area of study across clinical trials of vaccines and therapies against cancer, trauma, as well as autoimmune and infectious diseases. There is a need for effective protocols which maximally use the possibilities offered by modern flow cytometers to characterize such immune cell changes in peripheral blood using small volumes of human blood. Additionally, longitudinal clinical studies often use cryopreserved samples, which can impact flow cytometric results. To efficiently gauge both the innate and the adaptive immune response, two novel 15-color antibody panels to identify key myeloid and T cell subsets and their functional potential were established. This approach was used to compare cellular immune profiles in fresh whole blood and in matched cryopreserved peripheral blood mononuclear cells (PBMCs). Cocktail I was designed to identify and characterize myeloid cell populations including dendritic cells (DCs), monocytic monocyte-derived suppressor cells (MO-MDSC), and monocytes, determining further core aspects of their state of maturity, T cell stimulatory (or inhibitory) potential, and migration capability. Cocktail II was used for phenotyping diverse T cells subsets, and their key migration and functional regulatory capabilities. The two 15-color antibody panels for the evaluation of both immune-stimulating and immunosuppressive processes presented herein allowed for efficient evaluation of the balance of immune activation versus immunosuppression across key blood cells, with good resolution for all 15 markers stained for in each panel. Gating strategies for the myeloid and T cells are presented to further support specific subset identification. This protocol was shown to be reproducible across donors and useful to study both RBC-lysed whole blood and cryopreserved PBMCs. © 2017 International Society for Advancement of Cytometry.
Asunto(s)
Citometría de Flujo/métodos , Inmunofenotipificación/métodos , Células Mieloides/citología , Subgrupos de Linfocitos T/citología , Criopreservación , Humanos , Inmunidad Innata , Leucocitos Mononucleares/citologíaRESUMEN
Dendritic cells (DC) targeting vaccines require high efficiency for uptake, followed by DC activation and maturation. We used magnetic vectors comprising polyethylenimine (PEI)-coated superparamagnetic iron oxide nanoparticles, with hyaluronic acid (HA) of different molecular weights (<10 and 900 kDa) to reduce cytotoxicity and to facilitate endocytosis of particles into DCs via specific surface receptors. DNA encoding Plasmodium yoelii merozoite surface protein 1-19 and a plasmid encoding yellow fluorescent gene were added to the magnetic complexes with various % charge ratios of HA: PEI. The presence of magnetic fields significantly enhanced DC transfection and maturation. Vectors containing a high-molecular-weight HA with 100% charge ratio of HA: PEI yielded a better transfection efficiency than others. This phenomenon was attributed to their longer molecular chains and higher mucoadhesive properties aiding DNA condensation and stability. Insights gained should improve the design of more effective DNA vaccine delivery systems.
Asunto(s)
Compuestos Férricos/metabolismo , Ácido Hialurónico/farmacología , Polietileneimina/química , Polietileneimina/metabolismo , Vacunas de ADN/administración & dosificación , Vacunas de ADN/química , Animales , Antígenos de Protozoos/genética , Células Dendríticas , Compuestos Férricos/química , Vectores Genéticos , Fenómenos Magnéticos , Ratones Endogámicos C57BL , Nanopartículas/administración & dosificación , Nanopartículas/efectos adversos , Nanopartículas/química , Plasmodium yoelii/genética , TransfecciónRESUMEN
BACKGROUND: The need for coronavirus 2019 (COVID-19) vaccination in different age groups and populations is a subject of great uncertainty and an ongoing global debate. Critical knowledge gaps regarding COVID-19 vaccination include the duration of protection offered by different priming and booster vaccination regimens in different populations, including homologous or heterologous schedules; how vaccination impacts key elements of the immune system; how this is modified by prior or subsequent exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and future variants; and how immune responses correlate with protection against infection and disease, including antibodies and effector and T cell central memory. METHODS: The Platform Trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, multi-arm, Bayesian, adaptive, randomised controlled platform trial. PICOBOO will expeditiously generate and translate high-quality evidence of the immunogenicity, reactogenicity and cross-protection of different COVID-19 priming and booster vaccination strategies against SARS-CoV-2 and its variants/subvariants, specific to the Australian context. While the platform is designed to be vaccine agnostic, participants will be randomised to one of three vaccines at trial commencement, including Pfizer's Comirnaty, Moderna's Spikevax or Novavax's Nuvaxovid COVID-19 vaccine. The protocol structure specifying PICOBOO is modular and hierarchical. Here, we describe the Core Protocol, which outlines the trial processes applicable to all study participants included in the platform trial. DISCUSSION: PICOBOO is the first adaptive platform trial evaluating different COVID-19 priming and booster vaccination strategies in Australia, and one of the few established internationally, that is designed to generate high-quality evidence to inform immunisation practice and policy. The modular, hierarchical protocol structure is intended to standardise outcomes, endpoints, data collection and other study processes for nested substudies included in the trial platform and to minimise duplication. It is anticipated that this flexible trial structure will enable investigators to respond with agility to new research questions as they arise, such as the utility of new vaccines (such as bivalent, or SARS-CoV-2 variant-specific vaccines) as they become available for use. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry ACTRN12622000238774. Registered on 10 February 2022.
Asunto(s)
COVID-19 , Vacunas , Humanos , SARS-CoV-2 , COVID-19/prevención & control , Vacunas contra la COVID-19 , Teorema de Bayes , Australia , Vacunación , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Variation in epitopes of infectious pathogens inhibits various effector functions of T lymphocytes through antagonism of the T-cell receptor. However, a more powerful strategy for immune evasion would be to prevent the induction of T-cell responses. We report here mutual 'interference' with the priming of human T-cell responses by a pair of naturally occurring variants of a malaria cytotoxic T-cell epitope. Interference with priming also occurs in vivo for a murine malaria T-cell epitope. Reshaping of the T-cell repertoire by such immune interference during naive T-cell induction may provide a general mechanism for observed patterns of immunodominance and persistence by many polymorphic pathogens.
Asunto(s)
Variación Antigénica , Antígenos de Protozoos/inmunología , Activación de Linfocitos , Malaria Falciparum/inmunología , Linfocitos T/inmunología , Presentación de Antígeno , Epítopos , Humanos , Ligandos , Fragmentos de Péptidos/inmunología , Proteínas Protozoarias/inmunología , Receptores de Antígenos de Linfocitos T/inmunología , Linfocitos T CitotóxicosRESUMEN
Host-parasite coevolution has been likened to a molecular arms race, with particular parasite genes evolving to evade specific host defenses. Study of the variants of an antigenic epitope of Plasmodium falciparum that induces a cytotoxic T cell response supports this view. In African children with malaria, the variants present are influenced by the presence of a human leukocyte antigen (HLA) type that restricts the immune response to this epitope. The distribution of parasite variants may be further influenced by the ability of cohabiting parasite strains to facilitate each other's survival by down-regulating cellular immune responses, using altered peptide ligand antagonism.
Asunto(s)
Antígenos de Protozoos/inmunología , Antígeno HLA-B35/inmunología , Malaria Falciparum/inmunología , Plasmodium falciparum/inmunología , Proteínas Protozoarias/inmunología , Linfocitos T Citotóxicos/inmunología , Alelos , Animales , Antígenos de Protozoos/genética , Evolución Biológica , Niño , Epítopos , Evolución Molecular , Gambia , Genes Protozoarios , Variación Genética , Humanos , Ligandos , Malaria Falciparum/parasitología , Modelos Biológicos , Plasmodium falciparum/genética , Proteínas Protozoarias/genéticaRESUMEN
INTRODUCTION: The challenge to eradicate malaria is an enormous task that will not be achieved by current control measures, thus an efficacious and long-lasting malaria vaccine is required. The licensing of RTS, S/AS01 is a step forward in providing some protection, but a malaria vaccine that protects across multiple transmission seasons is still needed. To achieve this, inducing beneficial immune responses while minimising deleterious non-targeted effects will be essential. AREAS COVERED: This article discusses the current challenges and advances in malaria vaccine development and reviews recent human clinical trials for each stage of infection. Pubmed and ScienceDirect were searched, focusing on cell mediated immunity and how T cell subsets might be targeted in future vaccines using novel adjuvants and emerging vaccine technologies. EXPERT COMMENTARY: Despite decades of research there is no highly effective licensed malaria vaccine. However, there is cause for optimism as new adjuvants and vaccine systems emerge, and our understanding of correlates of protection increases, especially regarding cellular immunity. The new field of heterologous (non-specific) effects of vaccines also highlights the broader consequences of immunization. Importantly, the WHO led Malaria Vaccine Technology Roadmap illustrates that there is a political will among the global health community to make it happen.
Asunto(s)
Inmunización/métodos , Vacunas contra la Malaria/administración & dosificación , Malaria/prevención & control , Adyuvantes Inmunológicos/administración & dosificación , Salud Global , Humanos , Inmunidad Celular/inmunología , Malaria/epidemiología , Malaria/inmunología , Estaciones del Año , Factores de TiempoRESUMEN
As global malaria mortality increases the urgency for vaccine development, analysis of immune responses in naturally exposed populations is providing clues to the nature of protective immunity. Recently, sophisticated immune evasion strategies adopted by the parasite have been analysed at the molecular level. More immunogenic vaccination strategies have been identified, providing renewed optimism that effective malaria control through vaccination should be feasible.
Asunto(s)
Malaria/inmunología , Animales , Enfermedades Endémicas , Eritrocitos/inmunología , Células Madre Hematopoyéticas/inmunología , Humanos , Malaria/epidemiología , Malaria/prevención & controlRESUMEN
Ty virus-like particles consist of a single protein species that can be produced in yeast. Recombinant Ty-VLPs carrying a string of up to 15 defined cytotoxic T lymphocyte (CTL) epitopes from Plasmodium species prime protective CTL responses in mice following a single administration without adjuvant. Effective processing of epitopes from the string was demonstrated in vitro and in vivo and was not affected by flanking sequences.
Asunto(s)
Epítopos/química , Vacunas contra la Malaria/química , Plasmodium falciparum/inmunología , Secuencia de Aminoácidos , Animales , Epítopos/inmunología , Femenino , Humanos , Vacunas contra la Malaria/inmunología , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Plasmodium berghei/inmunología , Linfocitos T Citotóxicos/inmunologíaRESUMEN
In hepatocytes obtained from hypothyroid rats, phorbol myristate acetate (PMA) and vasopressin diminished the accumulation of cyclic AMP and the stimulation of ureagenesis induced by isoprenaline or glucagon without altering significantly the accumulation of cyclic AMP induced by forskolin. Pretreatment with PMA markedly reduced the stimulation of ureagenesis and the accumulation of cyclic AMP induced by isoprenaline or glucagon. In membranes from cells pretreated with PMA, the stimulation of adenylate cyclase induced by isoprenaline + GTP, glucagon + GTP or by Gpp[NH]p were clearly diminished as compared to the control, whereas forskolin-stimulated activity was not affected. The data indicate heterologous desensitization of adenylate cyclase. It was also observed that the homologous (García-Sáinz J.A. and Michel, B. (1987) Biochem. J. 246, 331-336) and this heterologous beta-adrenergic desensitizations were additive. Pertussis toxin treatment markedly reduced the heterologous desensitization of adenylate cyclase but not the homologous beta-adrenergic desensitization. It is concluded that the homologous and heterologous desensitizations involve different mechanisms. The homologous desensitization seems to occur at the receptor level, whereas the heterologous probably involves the guanine nucleotide-binding regulatory protein, Ns.
Asunto(s)
Toxina de Adenilato Ciclasa , Adenilil Ciclasas/metabolismo , Hígado/metabolismo , Toxina del Pertussis , Receptores Adrenérgicos beta/fisiología , Factores de Virulencia de Bordetella/farmacología , Animales , Colforsina/farmacología , AMP Cíclico/biosíntesis , Interacciones Farmacológicas , Activación Enzimática/efectos de los fármacos , Femenino , Glucagón/farmacología , Guanosina Trifosfato/farmacología , Guanilil Imidodifosfato/farmacología , Hipotiroidismo/metabolismo , Isoproterenol/farmacología , Hígado/efectos de los fármacos , Propranolol/farmacología , Proteína Quinasa C/metabolismo , Ratas , Ratas Endogámicas , Receptores Adrenérgicos beta/efectos de los fármacos , Acetato de Tetradecanoilforbol/farmacología , Urea/biosíntesis , Vasopresinas/farmacologíaRESUMEN
The immune system is a tightly regulated network that is able to maintain a balance of immune homeostasis under normal physiological conditions. Normally, when challenged with foreign antigen, specific appropriate responses are initiated that are aimed at restoring homeostasis. However under particular circumstances, this balance is not maintained and immune responses either under or over react. Cancer is an example of a situation where the immune response can be inefficient or unresponsive, resulting in uncontrolled growth of the cancer cells. Conversely, when the immune response over-reacts, this can result in conditions such as autoimmunity or pathology following infection. Many drug therapies have been developed that aim to alleviate or prevent such immune disorders and restore immune homeostasis. This review highlights recent advances in immunotherapies, with an emphasis on specific examples in the treatment of cancer, autoimmune disease (multiple sclerosis) and viral infection (respiratory syncytial virus).
Asunto(s)
Enfermedades Autoinmunes/inmunología , Homeostasis/inmunología , Inmunoterapia , Neoplasias/inmunología , Virosis/inmunología , Animales , Enfermedades Autoinmunes/terapia , Humanos , Inmunoterapia/métodos , Neoplasias/terapia , Virosis/terapiaRESUMEN
The major outer layer protein, VP7, of the simian rotavirus SA11 has been synthesized in Escherichia coli, under the control of the lac promoter, as a fusion polypeptide with beta-galactosidase (beta Gal). The viral protein in the hybrid polypeptide is missing its N-terminal hydrophobic region and 26 amino acids (aa) at its C-terminus; it is flanked at both ends by beta Gal sequences. We have purified the hybrid 145-kDa protein by affinity chromatography using a column specific for beta Gal. Unexpectedly, a second protein of 118-kDa was also specifically bound to the column. N-terminal aa sequence analysis of these two proteins showed that the 145-kDa protein represented the expected fusion product, whereas the 118-kDa protein was apparently the result of initiation of translation at an internal site close to the 3' end of the viral sequence, in the chimeric mRNA. Each of the two polypeptides represented about 2 to 3% of the total protein of the recombinant-plasmid-carrying bacteria. When a bacterial lysate enriched for the hybrid polypeptides was injected into mice, it induced neutralizing antibodies to SA11 rotavirus.
Asunto(s)
Cápside/genética , Escherichia coli/genética , Rotavirus/genética , Cápside/biosíntesis , Escherichia coli/metabolismo , Genes Virales , Plásmidos , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genética , beta-Galactosidasa/genéticaRESUMEN
The development of a vaccine for cancer has been difficult compared to the effective vaccines of infectious diseases. Most tumor antigens are not entirely foreign and are expressed on normal tissues, thus, making it difficult to induce strong immune responses against self antigens. A peptide mimic, however, may have the potential to generate greater immune responses than those induced to self peptides. In this review we discuss applications of peptide mimics for cancer immunotherapy which may ultimately prove useful in humans.
Asunto(s)
Antígenos de Neoplasias/inmunología , Vacunas contra el Cáncer/inmunología , Imitación Molecular , Neoplasias/terapia , Péptidos/química , Animales , Anticuerpos Antiidiotipos/inmunología , Enfermedades Autoinmunes/inmunología , Diseño de Fármacos , Humanos , Inmunoterapia Activa , Modelos Moleculares , Biblioteca de Péptidos , Péptidos/inmunologíaRESUMEN
The optimum culture conditions to support in vitro proliferative responses to conventional soluble protein antigens by human CD4+ T cells from healthy non-immunised donors have been determined. These responses were blocked by anti-HLA-DR monoclonal antibodies (mAbs) and were strictly dependent on the presence of antigen-presenting cells (APCs). Primary responses showed a reproducible pattern of proliferation kinetics which distinguished them from secondary in vitro T cells reactions. T cells specific for the sensitising antigen were recovered from primary cultures.
Asunto(s)
Activación de Linfocitos/inmunología , Linfocitos T/inmunología , Adyuvantes Inmunológicos , Anticuerpos Monoclonales , Células Presentadoras de Antígenos/inmunología , Antígenos/inmunología , Células Cultivadas , Antígenos HLA-DR/inmunología , Hemocianinas/inmunología , Humanos , Inmunofenotipificación , Antígenos Comunes de Leucocito/inmunología , Reproducibilidad de los Resultados , Solubilidad , Tuberculina/inmunología , gammaglobulinas/inmunologíaRESUMEN
Vaccination has eradicated smallpox and greatly decreased mortality and morbidity associated with a variety of viral and bacterial infectious diseases. However, conventional methodologies have failed to provide vaccines against many widespread deadly human diseases, among them HIV, malaria and cancer. Recombinant DNA vaccines have shown great promise in animal models in inducing protective immunity. In this review we will discuss their potential safe use in humans following recent advances in their use in animals, including non-human primates.
Asunto(s)
Vacunas de ADN/uso terapéutico , Animales , Presentación de Antígeno , Antígenos/administración & dosificación , Antígenos/genética , Biotecnología , Ensayos Clínicos como Asunto , ADN Recombinante , Humanos , Activación de Linfocitos , Primates , Seguridad , Linfocitos T/inmunología , Vacunas de ADN/efectos adversos , Vacunas de ADN/inmunologíaRESUMEN
The merozoite surface protein-1 (MSP1) is the most studied malaria blood-stage vaccine candidate. Lymphokines such as interferon gamma (IFN-gamma) and interleukin 4 (IL-4) may mediate blood-stage specific protection. Here we identify Plasmodiumfalciparum MSP1 T-cell epitopes capable of rapid induction of IFN-gamma and/or IL-4 from peripheral blood mononuclear cells of East and West African donors. Both allelic forms of these novel MSP1 T-cell epitopes were stimulatory. An unusually high numbers of Gambian responders (> 80%) to these epitopes were observed, suggesting that MSPI reactivity may have been underestimated previously in this population. Surprisingly, IFN-gamma responses to allelic T-cell epitopes failed to correlate with differential antigenic exposure in The Gambia compared to Kenya. These results suggest an unexpected level of immunoregulation of IFN-gamma response with variable allelic T-cell reactivity independent of the level of antigenic exposure. Further analysis of the mechanisms determining this response pattern may be required if vaccines are to overcome this allelic reactivity bias in malaria-exposed populations.
Asunto(s)
Epítopos de Linfocito T/inmunología , Proteína 1 de Superficie de Merozoito/inmunología , Plasmodium falciparum/inmunología , Linfocitos T/inmunología , Adolescente , Adulto , Alelos , Secuencia de Aminoácidos , Animales , Estudios de Casos y Controles , Cartilla de ADN , Femenino , Gambia/epidemiología , Humanos , Interferón gamma/inmunología , Interleucina-4/inmunología , Kenia/epidemiología , Malaria Falciparum/epidemiología , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , PrevalenciaRESUMEN
A generic approach to inducing high level CD8+ T cell responses would be of value for prophylactic and therapeutic immunisation against several infectious diseases. However, it has been very difficult to achieve such immune responses using available vaccination strategies. Malaria is one of several diseases against which a new generation of better CD8+ T cell-inducing vaccines might be useful and is unusual in that it allows assessment of vaccine efficacy in small numbers of volunteers in carefully controlled challenge studies. Here we review the identification of a heterologous prime-boost regime using DNA priming and recombinant modified vaccinia Ankara (MVA) boosting that induces high level T cell responses in both mice and non-human primates. Clinical trials to determine whether this prime-boost approach is immunogenic in humans are in progress.
Asunto(s)
Vacunas contra la Malaria/administración & dosificación , Vacunas de ADN/administración & dosificación , Adyuvantes Inmunológicos/administración & dosificación , Animales , Linfocitos T CD8-positivos/inmunología , Ensayos Clínicos Fase I como Asunto , Vectores Genéticos , Humanos , Inmunización Secundaria , Inmunoensayo , Hígado/parasitología , Malaria/inmunología , Malaria/parasitología , Malaria/prevención & control , Primates , Virus Vaccinia/genética , Virus Vaccinia/inmunologíaRESUMEN
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of myeloid progenitors that can play a major role in tumour development and chronic inflammation. The importance of the suppressive function ofMDSCs was first suggested by studies involving cancer patients and cancer-bearing mice. In addition, recent studies have demonstrated that MDSCs can also be involved in many other pathological conditions. MDSCs have unique ways of abrogatingan immune response in addition to those utilised by other immune-suppressive cell types, for example via the induction of arginase-1 and consequent upregulation in reactive oxygen species (ROS) production. Due to their heterogeneity,they further can express a variety of lineage markers, which overlap with other myeloid cell types such as Gr1,CD11b, MHCIIlo, Ly6C and Ly6G, making it difficult to identify them by surface phenotype alone. The disparity between mouse and human MDSCs further complicates the identification of these elusive cell populations. In this review, we will summarise the recent updates on the methods for eliciting and studying different MDSC subsets, including newly proposed surface phenotypes, as well as insights into how their function is being characterised in both mice and humans. In addition, exciting new discoveries suggesting their involvement across a number of different pathological settings, such as sepsis, autoimmunity and Leishmaniasis, will be discussed.
Asunto(s)
Tolerancia Inmunológica , Células Progenitoras Mieloides/inmunología , Células Progenitoras Mieloides/patología , Neoplasias/inmunología , Animales , Humanos , Inflamación/inmunología , Inflamación/patología , Células Progenitoras Mieloides/citología , Neoplasias/patologíaAsunto(s)
Proteínas de la Cápside , Cápside/inmunología , Rotavirus/inmunología , Salmonella typhimurium/inmunología , Animales , Antígenos Virales/genética , Cápside/biosíntesis , Cápside/genética , Ratones , Ratones Endogámicos BALB C , Plásmidos , Rotavirus/genética , Salmonella typhimurium/genética , Vacunas Sintéticas/genética , Vacunas Sintéticas/aislamiento & purificaciónRESUMEN
The alveolar macrophage (AM) is believed to be of central importance in the immune response against infection and tumour. We examined patients with lung cancer in order to evaluate the immuno-stimulatory potential of AM in lung cancer. Bronchoalveolar lavage fluid samples were obtained from patients with adenocarcinoma, squamous cell carcinoma, large cell undifferentiated lung carcinoma, small cell carcinoma and control subjects. AM were isolated and phagocytic function, flow cytometry and cytokine analysis were assessed. AM from patients with small and squamous cell carcinoma had impaired uptake in vitro of 40 nm fluorescent polystyrene beads. AM from patients with small, squamous and large cell undifferentiated carcinoma showed impaired uptake of 1000 nm fluorescent polystyrene beads. Secreted levels of TNF-alpha and IL-1 from AM of patients with small, squamous, and large cell undifferentiated carcinoma were decreased compared to controls. Secreted AM IL-6 levels were decreased in small and large cell undifferentiated carcinoma. AM from adenocarcinoma patients showed similar levels of IL-10, IL-6, IL-1 and TNF-alpha compared to controls. Phenotypic analysis demonstrated that patients with small cell carcinoma were the only group that showed a decrease in MHC class II surface expression. Surface expression of ICAM-1 and CD83 was decreased on AM from patients with large, squamous and small cell carcinoma compared to controls but not adenocarcinoma. Mannose receptor levels were only decreased on AM from patients with squamous and small cell carcinoma but not adenocarcinoma and large cell undifferentiated carcinoma. We conclude that there are type-specific alterations in uptake ability, cytokine secretion and phenotype of AM from lung cancer patients, which may result in an inability to stimulate anti-tumour immunity. The observed differences between lung cancer subgroups may explain previously reported inconsistencies in descriptions of AM characteristics in lung cancer.